Crescent Capital BDC Earnings Call Transcripts
Fiscal Year 2026
-
Q3 NII rose to $0.37/share and covered the $0.34 regular dividend; NAV was $17.72/share. A planned JV and up to $75 million in share purchases aim to reduce leverage and capture the stock discount amid subdued LBO activity.
-
Net investment income declined to $0.36 per share, but earnings exceeded the base dividend. NAV fell to $17.82 per share, mainly due to unrealized losses on non-accruals, while leverage rose above target but is expected to normalize in the second half. Portfolio rotation and de-leveraging remain key priorities.
-
The meeting confirmed quorum and proceeded with the election of two directors for terms expiring in 2029 and ratified Ernst & Young LLP as auditor for 2026. No shareholder questions were submitted during the session.
-
NAV and NII declined due to increased non-accruals, especially in healthcare, but portfolio risk ratings remain stable. Management and incentive fees were reduced, the base dividend was reset, and Sun Life completed its acquisition of Crescent Capital.
Fiscal Year 2025
-
Q4 2025 net investment income was $0.45 per share, covering the dividend, with NAV per share declining to $19.10 due to unrealized losses. Portfolio remains diversified and first lien-focused, while management reviews dividend and fee structure amid lower rates.
-
Net investment income held steady at $0.46 per share, with strong dividend coverage and a stable, diversified portfolio. NAV declined due to tariff-related losses, but liquidity and capital structure remain robust, supporting continued investment and dividend stability.
-
Net investment income rose to $0.46 per share ($0.48 adjusted), with strong dividend coverage and stable portfolio yields. NAV per share dipped slightly due to a special dividend, while credit quality remains robust and risk management proactive amid ongoing market volatility.
-
Net investment income declined sequentially due to lower base rates, runoff of one-time items, and increased non-accruals, but portfolio diversification and first-lien focus helped mitigate impacts. Dividend was maintained, leverage remains within target, and market uncertainty from tariffs has slowed deal activity.
Fiscal Year 2024
-
Q4 NII declined to $0.55 per share, with NAV per share at $19.98 and strong dividend coverage. Portfolio quality remains high, with low non-accruals and increased watchlist assets, while new investments focused on first-lien loans. Leverage and liquidity remain within targets.
-
Q3 2024 saw strong net investment income and stable credit performance, with a diversified portfolio and low non-accruals. Management expects increased deal activity in 2025, supported by ample liquidity and a focus on first-lien, sponsor-backed loans.
-
Q2 2024 saw strong credit performance, with NII of $0.59 per share and NAV rising to $20.30. The portfolio remains highly diversified, with 90% in first lien loans and low nonaccruals. Leverage increased to 1.18x, and liquidity is robust, supporting continued dividend coverage.